EGFR-mutant lung cancers are one of the most frequent molecularly defined subsets accounting for approximately 40% in East Asians with lung adenocarcinoma, and agents targeted EGFR have been the first-line therapy for NSCLC patients with EGFR mutation [56]. This evidence concerns the gene EGFR and lung carcinoma.